Ultime notizie per Olaplex Hldgs (NASDAQ:OLPX) Azioni

OLAPLEX HOLDINGS INC

Olaplex Hldgs

Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.

<p><strong>Able View Global Inc. – (NASDAQ:</strong><a href="https://www.benzinga.com/stock/ABLV#NASDAQ"><strong>ABLV</strong></a><strong>) ("Able View" or the "Company") </strong>one of the largest comprehensive brand management partners of international beauty and personal care brands in China, Able View partnership with TikTok key opinion leaders ("KOLs") to expand distribution channels.</p>
<p>In Able View's continuous efforts to explore new business channels and growth opportunities, the Company has entered into strategic partnerships with multiple prominent TikTok KOLs. These partnerships will promote the distribution of the premium brands represented by the Company through TikTok live-streaming activities ("DaBo"). This initiative will further consolidate the business development of the TikTok platform, strengthen the Company's market leadership and core competitiveness, and provide brand partners with optimized marketing solutions and more comprehensive service support.</p>


News

ABLV

Able View Partners With TikTok Influencers To Boost Brand Distribution And Expand Live-Stream Sales In China

<p>Morgan Stanley  analyst Patrick Wood   maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Equal-Weight and raises the price target from $75 to $81.</p>


Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Edwards Lifesciences, Raises Price Target to $81

<p><strong>Consortium Including Eco Wave Power Secures €2.45 Million Grant to Deploy Scalable</strong></p>
<p><strong>Wave Energy&nbsp;Solutions Across Atlantic Region</strong></p>
<p>&nbsp;</p>
<p><strong>Stockholm, Sweden</strong> — July 10, 2025 — Eco Wave Power Global AB (publ) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVE#NASDAQ">WAVE</a>) ("Eco Wave Power" or the "Company"), a leader in onshore wave energy technology, is proud to announce its participation in the Atlantic Wave Energy Sustainable Deployment Initiative (AWESDI) – a newly approved €2.45 million transnational project funded under the Interreg Atlantic Area Programme's Third Call for Proposals.</p>
<p>The project, which targets Priority 2.1 of the Atlantic Area Programme, promoting energy efficiency and reducing greenhouse gas emissions, aims to advance the sustainable and scalable deployment of wave energy technologies in Atlantic coastal regions.</p>
<p>The Atlantic Area Programme, co-funded by the European Union through the European Regional Development Fund (ERDF), supports transnational cooperation projects that advance sustainable development and regional cohesion in Atlantic coastal regions. The approved projects span key areas such as climate resilience, renewable energy, and blue innovation—reinforcing Eco Wave Power's role at the forefront of the global clean energy transition.</p>
<p>&nbsp;</p>
<p>The AWESDI project is coordinated by the Centro de Investigación Mariña (CIM) of the University of Vigo and brings together an international consortium of top research institutions, private sector leaders, and government organizations from Portugal, Spain, France, and Ireland. In addition to Eco Wave Power, project partners include:</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Universidade do Porto (Portugal)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Université Le Havre Normandie (France)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>University College Cork (Ireland)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Marine Institute (Ireland)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>GEPS Techno (France)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Groupe Legendre (France)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Fundamar (Spain)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Pôle Mer Bretagne Atlantique (France)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Atlantic Technological University (Ireland)</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Xunta de Galicia (Spain)</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>As part of its contribution, Eco Wave Power will:</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Support feasibility studies for onshore and nearshore deployment sites in Portugal;</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Provide operational insights and performance data from existing wave energy installations;</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Validate the Sustainable Design Toolkit and inform permitting and deployment planning; and</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Contribute to the development of the Wave Energy Deployment Roadmap from an industry perspective.</td>
</tr>
</tbody>
</table>
<p></p></figure></p>


Contracts

Global

WAVE

Eco Wave Power Announces That On July 10, 2025 It Participated In €2.45M EU-Funded Consortium To Advance Scalable Wave Energy Across Atlantic Region

<p>— <i>Doubles its general purpose, secure control device options with new Certus-NX and MachXO5-NX FPGA devices —</i></p>
<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.latticesemi.com&amp;esheet=54288511&amp;newsitemid=20250715222230&amp;lan=en-US&amp;anchor=Lattice+Semiconductor&amp;index=1&amp;md5=60ea7acbf6a0f7264dc59224812ee718">Lattice Semiconductor</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>), the low power programmable leader, today announced that the company expanded its small FPGA portfolio with new, high I/O density options in the Lattice Certus&#x2122;-NX FPGA and Lattice MachXO5&#x2122;-NX FPGA device families. The new offerings include multiple logic density and I/O options in a variety of new packages. These new devices are ideal for a wide range of solutions that require low power consumption, a small form factor, high 3.3V I/O, and security capabilities—making them well-suited for power-constrained AI, Industrial, Communications, Server, and Automotive applications.</p>


LSCC

Lattice Semiconductor Expands Small FPGA Portfolio With High I/O Density Options In Lattice Certus-NX FPGA And Lattice MachXO5-NX FPGA Device Families

<p><a href="https://aws.amazon.com/blogs/machine-learning/aws-doubles-investment-in-aws-generative-ai-innovation-center-marking-two-years-of-customer-success/" title="https://aws.amazon.com/blogs/machine-learning/aws-doubles-investment-in-aws-generative-ai-innovation-center-marking-two-years-of-customer-success/">https://aws.amazon.com/blogs/machine-learning/aws-doubles-investment-in-aws-generative-ai-innovation-center-marking-two-years-of-customer-success/</a></p>


AMZN

'AWS Doubles Investment In AWS Generative AI Innovation Center, Marking Two Years Of Customer Success' - Amazon

<p>Barclays  analyst Lauren Lieberman   maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Equal-Weight and raises the price target from $86 to $87.</p>


Barclays Maintains Equal-Weight on Colgate-Palmolive, Raises Price Target to $87

TTEK

Tetra Tech Wins $94M EPA Contract

<p><i>Callan JMB Services (India) Private Limited to offer logistics services in India, with a planned warehouse in Pune, Maharashtra for storage and distribution of pharmaceuticals at all temperature ranges</i></p>
<p><strong>SPRING BRANCH, Texas, July 15, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJMB#NASDAQ">CJMB</a>) ("Callan JMB" or the "Company"), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that it has formed Callan JMB Services (India) Private Limited to offer logistics services in India. The subsidiary has a management office and will soon have an operational warehouse in Pune, Maharashtra, India for storage and distribution of pharmaceuticals at all temperature ranges, including -80○C, needed for storing tissue samples for clinical trials.</p>
<p>On June 20, 2025, Callan JMB incorporated its India business subsidiary, Callan JMB Services (India) Private Limited, to distribute pharmaceutical and wellness products within India. In addition, the U.S. Callan JMB Services (India) Private Limited will also assist Indian companies in establishing onshore manufacturing plants in the U.S. The newly incorporated company already has an agreement with Walker's Pharmaceuticals Ltd. and is working with Brihans Natural Products Ltd. to assist both companies in establishing U.S. manufacturing plants, acting as distributors of their products in the U.S.</p>


CJMB

Callan JMB Launches India Subsidiary With Pune Warehouse To Expand Pharma Logistics And Support U.S. Manufacturing Partnerships

<p>Barclays  analyst Lauren Lieberman   maintains Coca-Cola Europacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCEP#NASDAQ">CCEP</a>) with a Overweight and raises the price target from $101 to $104.</p>


Coca-Cola European Partners plc Ordinary Shares

CCEP

Barclays Maintains Overweight on Coca-Cola Europacific, Raises Price Target to $104

<p>Morgan Stanley  analyst Patrick Wood   maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Underweight and lowers the price target from $28 to $27.</p>


Morgan Stanley Maintains Underweight on Baxter Intl, Lowers Price Target to $27

Biotech

General

ENVB

Enveric Biosciences Announces Results In Preclinical, Exposure-Based Therapeutic Model For PTSD Showing EB-003 Decreased Context-Induced Freezing Behavior One Hour Post Dose

<p><strong>Wells Fargo &amp; Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) reported a net interest income of $11.71 billion on Tuesday, down 2% year over year in the&nbsp;second quarter of 2025.</p>
<p>Lower net interest income was driven by the impact of lower interest rates on floating rate assets and deposit mix changes, partially offset by lower market funding and deposit pricing.</p>
<p>The bank reported earnings of $1.60 per share, beating the consensus of $1.40. &nbsp;Revenue increased 1% year over year to $20.82 billion. Analysts <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">expected $20.78 billion</a>.</p>
<p>Noninterest income increased 4%, and included the gain associated with the merchant services joint venture acquisition, an increase in asset-based fees in Wealth and Investment Management on higher market valuations, and higher investment banking fees, partially offset by lower net gains from trading in the Markets business.</p>
<p><strong><em>Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/07/46410553/us-stock-futures-trade-mixed-ahead-of-june-inflation-print-big-banks-in-focus-as-street-awaits-jpmorgan-wells-fargo-bny-mellon-citibanks-earnings" rel="noreferrer noopener">US Stock Futures Trade Mixed Ahead Of June Inflation Print: Big Banks In Focus As Street Awaits JPMorgan, Wells Fargo, BNY Mellon, Citibank&#8217;s Earnings</a></em></strong></p>
<p>Corporate and Investment Banking revenues <a target="_blank" href="https://www.wellsfargo.com/assets/pdf/about/investor-relations/earnings/second-quarter-2025-earnings.pdf" rel="noreferrer noopener">decreased</a> 3% to $4.67 billion.</p>
<p>Banking was down 7%, driven by lower interest rates, partially offset by lower deposit pricing and higher investment banking revenue, including higher advisory fees.</p>
<p>Commercial Real Estate was down 6% due to lower loan balances, the impact of lower interest rates, and lower mortgage banking income reflecting the sale of our commercial non-agency third-party servicing business in the first quarter of 2025.</p>
<p>These decreases were partially offset by higher revenue in the affordable housing business and increased capital markets activity.</p>
<p>Average loans were almost unchanged at $916.7 billion, as higher commercial and industrial loans largely offset declines in commercial real estate and residential mortgage loans. These loans were up $8.5 billion, or 1%, from the first quarter of 2025, driven by commercial and industrial loan growth.</p>
<p>Average deposits reached 1.33 trillion, down from 1.35 trillion a year ago. They were <a target="_blank" href="https://www.wellsfargo.com/assets/pdf/about/investor-relations/earnings/second-quarter-2025-financial-results.pdf" rel="noreferrer noopener">down</a> $14.8 billion, or 1%, due to a reduction in higher-cost CDs issued by Corporate Treasury; they were also down $7.6 billion, or 1%, from the first quarter of 2025.</p>
<h2 class="wp-block-heading">Outlook</h2>
<p>For fiscal year 2025, Wells Fargo expects net interest income to be roughly in line with the 2024 income of $47.7 billion.</p>
<p>In April, Wells Fargo&nbsp;expected net interest income to be ~1 to 3% higher than the 2024 net <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44759629/wells-fargo-doesnt-change-outlook-but-ceo-expects-volatility-and-slower-economic-environment-in-2025" rel="noreferrer noopener">interest income of $47.7 billion</a>.</p>
<p>In its second quarter earnings presentation, the bank says the largest driver of the change from prior guidance is lower net interest income in the Markets business, largely offset by higher noninterest income.</p>
<p>Wells Fargo expects 2025 noninterest expense to be ~$54.2 billion, unchanged from prior guidance.</p>
<p><strong>Price Action: </strong>WFC stock is trading lower by 3.27% to $80.70 during the premarket session at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><em><a href="https://www.benzinga.com/news/education/25/07/46410939/bidens-save-plan-crumbles-as-trump-team-ends-relief-short-window-before-interest-hits-7-7-million-borrowers-expert-warns" target="_blank" rel="noreferrer noopener">Biden&#8217;s SAVE Plan Crumbles As Trump Team Ends Relief: &#8216;Short Window&#8217; Before Interest Hits 7.7 Million Borrowers, Expert Warns</a></em></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Earnings

Large Cap

Guidance

Movers

Wells Fargo's Net Interest Income Shrinks In Q2, Bank Trims Outlook

<p><i><strong>One third of world's smokers live in China, which has highest rate of lung cancer</strong></i></p>
<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54290299&amp;newsitemid=20250715047187&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=ea0d4539c6903ad547fddf915bf8a6c0"><strong>bioAffinity Technologies, Inc.</strong></a><strong> (NASDAQ:</strong><a href="https://www.benzinga.com/stock/BIAF#NASDAQ"><strong>BIAF</strong></a><strong>, BIAFW)),</strong> a biotechnology company advancing early-stage cancer diagnostics including <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54290299&amp;newsitemid=20250715047187&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=31fa16bbb73bb1b8f50a9ca901b20fc0">CyPath&#xAE; Lung</a>, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry.</p>
<p>China represents a large prospective market for CyPath&#xAE; Lung with more than 300 million people who smoke, or a third of the world's total smokers, according to the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.who.int%2Fchina%2Fhealth-topics%2Ftobacco&amp;esheet=54290299&amp;newsitemid=20250715047187&amp;lan=en-US&amp;anchor=World+Health+Organization&amp;index=3&amp;md5=8a70cbdf82ff038d4b2c07b4f9ad65e0">World Health Organization</a>. The China cancer registry estimated 1.06 million new cases of lung cancer were diagnosed in 2022.</p>


BIAF

BIAFW

bioAffinity Technologies Receives Notification Of Allowance From CNIPA For Patent Application Related To Methods Of Predicting Likelihood Of Lung Cancer Using Flow Cytometry

<p>BTC Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) (the "Company"), a blockchain technology company, today announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $6.0 million of the Company's Ordinary Shares at a price of $3.00 per Ordinary Share. The offering consisted of the sale of 2,000,000 Ordinary Shares.</p>
<p>Aggregate gross proceeds to the Company are expected to be approximately $6.0 million before deducting fees to the placement agent and other expenses payable by the Company. The transaction is expected to close on or about July 16, 2025, subject to the satisfaction of customary closing conditions. <strong>The Company expects to use the net proceeds from the offering, together with its existing cash, for the purchase of Ethereum.</strong></p>
<p><strong>Aegis Capital Corp. is acting as exclusive placement agent for the offering. VCL Law LLP is acting as U.S. counsel to the Company. AllBright Law Offices is acting as PRC counsel to the Company. Conyers Dill &amp; Pearman is acting as Cayman counsel to the Company. Kaufman &amp; Canoles, P.C. is acting as counsel to Aegis Capital Corp.</strong></p>
<p>&nbsp;</p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

Markets

BTCT

BTC Digital Enters Into $6M Registered Direct Offering Of 2M Shares At $3.00 Per Share, To Fund Ethereum Purchases

<p>Morgan Stanley  analyst Patrick Wood   maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Equal-Weight and lowers the price target from $90 to $84.</p>


Morgan Stanley Maintains Equal-Weight on Alcon, Lowers Price Target to $84

<p><a href="https://www.benzinga.com/etfs">Money market funds</a> were the investment version of beige wallpaper for years, secure, utilitarian, but not often thrilling. Today, <strong>Simplify Asset Management </strong>is updating the asset class with the introduction of the <strong>Simplify Government Money Market ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBIL#NYSE">SBIL</a>), a fund that can behave like cash but trade like an ETF.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/07/46404616/ynot-invest-in-tech-horizons-new-etfs-balance-innovation-and-risk">YNOT Invest In Tech? Horizon&#8217;s New ETFs Balance Innovation And Risk</a></strong></p>
<p>As interest rate risk and income hunger compete among retail and institutional investors, SBIL emerges as a cash-equivalent solution that balances stability with flexibility. The fund invests at least 99.5% of its holdings in cash, U.S. government securities, and repo agreements collateralized by similar high-quality collateral. In other words, it&#8217;s a government money market fund, only in an ETF wrapper that trades all day on an exchange.</p>
<p><strong>David Berns</strong>, co-founder and CIO at Simplify, explains that the fund was created to provide investors with safety without compromising accessibility.</p>
<p>Unlike commonly understood money market mutual funds that have a daily priced, stable $1 NAV, SBIL has an intraday net asset value float and liquidity, enabling investors to trade in and out as they would a stock or an ETF. This could be helpful to anyone who dynamically manages cash allocations, whether a financial advisor who&#8217;s rebalancing a portfolio or a company temporarily parking short-term cash.</p>
<p>What differentiates SBIL isn&#8217;t the structure; it&#8217;s Rule 2a-7 compliance, a regulatory imprimatur that dictates how money market funds ensure liquidity and credit quality. That makes SBIL an attractive option for institutional treasurers and advisors who are shackled with strict investment policy statements but desire ETF convenience without compromising.</p>
<p>The ETF is calibrated to have a portfolio maturity of 60 days or shorter and a capped weighted average life of 120 days in accordance with regulatory requirements focused on capital preservation.</p>
<p><strong>Why It Matters:</strong> ETF sponsors are increasingly targeting the &#8220;cash on the sidelines,&#8221; a growing pool of funds, as investors remain risk-averse in the current macroeconomic environment. With yields still respectable and market volatility persisting, vehicles such as SBIL present a compromise: low risk, real yield, full liquidity.</p>
<p>For investors still parked in low-yield savings accounts or sweep funds, SBIL may offer the nudge toward more efficient cash management they didn't know they needed.</p>
<p><strong>Read Next:<a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46398559/are-your-tesla-etfs-secretly-betting-on-elon-musks-ai-startup"> </a></strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46398559/are-your-tesla-etfs-secretly-betting-on-elon-musks-ai-startup">Are Your Tesla ETFs Secretly Betting On Elon Musk&#8217;s AI Startup?</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


New ETFs

ETFs

Simplify Exchange Traded Funds Simplify Government Money Market ETF

SBIL

Investors Sitting On Cash? This New ETF Offers Modern Alternative

RANI

Rani Therapeutics Holdings Announces Pricing Of Registered Direct Offering For Gross Proceeds Of ~$3M

<p>Morgan Stanley  analyst David Lewis   maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Equal-Weight and raises the price target from $127 to $137.</p>


Morgan Stanley Maintains Equal-Weight on Abbott Laboratories, Raises Price Target to $137

<p><i>$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives</i></p>
<p><i>Discussions underway to expand adoption of ChemoFx in the U.S. and accelerate initial launch in Europe</i></p>
<p>PITTSBURGH, July 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>), a leader in AI-driven drug discovery, today issued the following shareholder update:</p>
<p>To my fellow Shareholders,</p>
<p>The past several weeks have been particularly noteworthy and productive at Predictive Oncology, and I wanted to take this opportunity to provide a brief recap of recent developments.</p>
<p><strong>Preparing for aggressive market expansion of ChemoFx&#xAE; in the U.S. and </strong><i><strong>de novo</strong></i><strong> Launch in Europe</strong></p>
<p>I'd like to begin with ChemoFx, which is our proprietary live-cell tumor profiling assay that uses a patient's own cells to measure chemotherapy responses <i>in vitro</i>, providing personalized guidance for treatment selection. By testing multiple chemotherapies on a patients' cancer cells before treatment selection, ChemoFx helps determine which chemotherapies are more likely to be effective on the tumor and which are less likely to provide benefit to the patient. With these data in-hand, oncologists can make better and faster treatment decisions – eliminating the current "trial-and-error" approach – which could go a long way towards improving patient outcomes while saving precious time and money.</p>
<p>This flagship assay, which stands as a renewable and extensible asset for the Company, was the primary assay by which the Company acquired more than 150,000 tumor samples, analyzed more than twenty-five years of drug response data and represents a significant opportunity for the Company to steadily augment the biobank, consistently develop novel drug response data and increase the likelihood of recurring revenue. The groundwork to expand availability of ChemoFx in the U.S is already underway, including meaningful and productive discussions with potential channel partners, and other end-users, including R&amp;D-based pharmaceutical manufacturers.</p>
<p>As we look to develop the next generation of ChemoFx, the Company anticipates the ability to extend beyond gynecological cancers, into other tumor types, including breast, colon and lung.</p>
<p>More importantly, the ability to obtain a patient tumor sample and monitor its growth and drug response as it transitions from a 2D cell culture to cryopreservation and then to 3D cell spheroids exemplifies the relevance and availability of our samples for high-throughput drug discovery, personalized medicine, and biomarker discovery. The utilization of cryopreserved dissociated tumor cells (DTCs) represents a scalable resource for research and clinical trials with viable primary tumor material.</p>
<p>The high throughput screening [HTS] market is projected to reach $69.5 billion by 2032, reflecting a CAGR of 12.18%,&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Oi2gaAxoC2iSo30sP3OER2H8gl40_-mtQz5o71xTSaBYsdRqSTSlGSPAmh7QEXuiU7meMC4hntXjLIJKuSRZdEUBgEDBKdHFMKCGoKdBkakrvOxq1RVs2CiMcvf1hTzWDAoEXeGuDE-bpO5vaoJQRHwbm1zXPTIZdkPEV4VbHUXWnkv9gnTmiw5mU8pMFw1Sttqed_7ipDRt-SbdbqVacQAbb1Mow3QbnjM60ujs5aFC0GY-qsd9TDi0TXuiy53HmRkLoTGWhNaQI7ZvyAnlyb9ndoZurp9kn2iV7GUzuZtunc23ovHueTB-gVxIY2lNoq-xSvrreXp3CeWrodXRpS-EQn3QAWWv5RJ5_DIToG8rvRE1-hxe4k1_dbWmqvzEhIBmep_OKO36EQfOGnioUrz3DJ1KmsSn3jFmmnFA773XUWBiEorQjUgpI8BXIlDc2j6iIKL_4xaTEDMQ8aIWHyDuAXehV5sktt-6hP8RhlxZAgSUIluHHXwAUpvCnhzJzFwXEwCPbqiZCv_UkuYDcdj_DVZRi8wjmmf9Rx8m82H3CnrBjj5mkoqj-JPEGkmx0N1VAgnWQVUmd02vPHRHeg==">according to SNS Insider research</a>. There is a growing adoption of 3D cell cultures which provide more physiologically relevant models for screening, enhancing the predictive power of HTS assays.</p>
<p>Collectively, these capabilities directly support the Company's AI-driven drug discovery initiatives by generating high-quality data that feeds into predictive models and supports biomarker discovery, companion diagnostics, and clinical trial design.</p>


Financing

POAI

Predictive Oncology Secures $10M Funding To Drive U.S. And European Expansion Of ChemoFx And Fuel AI-Driven Drug Discovery

<p>Barclays  analyst Lauren Lieberman   maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Underweight and lowers the price target from $129 to $119.</p>


Barclays Maintains Underweight on Clorox, Lowers Price Target to $119

Press Releases

Olaplex Holdings, Inc. to Report Third Quarter Fiscal 2024 Financial Results on November 7th

OLAPLEX Reports Third Quarter 2024 Results

Legal

Grabar Law Office Is Investigating Claims On Behalf of Long-Term Shareholders of Olaplex Holdings, Inc. (NASDAQ: OLPX); Telephone and Data Systems, Inc. (NYSE: TDS); Methode Electronics, Inc. (NYSE: MEI); and Equinix, Inc. (NASDAQ: EQIX)

Grabar Law Office is Investigating Claims On Behalf of Long-Term Shareholders of Extreme Networks, Inc. (NASDAQ: EXTR); Newmont Corporation (NYSE: NEM); Domino's Pizza Corp. (NASDAQ: DPZ); and Olaplex Holdings, Inc. (NASDAQ: OLPX)

GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON BEHALF OF LONG-TERM SHAREHOLDERS OF ORIGIN MATERIALS, INC. (NASDAQ: ORGN); OLAPLEX HOLDINGS, INC. (NASDAQ: OLPX); TELEPHONE AND DATA SYSTEMS, INC. (NYSE: TDS); AND METHODE ELECTRONICS, INC. (NYSE: MEI)

Olaplex Holdings, Inc. to Report Fourth Quarter and Fiscal 2024 Financial Results on March 4th

Olaplex Holdings, Inc. Announces Participation in the Raymond James 46th Annual Institutional Investors Conference on March 5th

OLAPLEX Reports Fourth Quarter and Fiscal Year 2024 Results

Olaplex Holdings, Inc. to Report First Quarter Fiscal 2025 Financial Results on May 8th

OLAPLEX Reports First Quarter 2025 Results

EQIX

EXTR

OLPX

ORGN

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Upexi

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Comments

Olaplex Hldgs

Notizie

Ultime notizie per Olaplex Hldgs (NASDAQ:OLPX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO